Press Release ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial 2 June 2025
Press Release Adtran expands Oscilloquartz atomic clock portfolio with lower-cost optical cesium solutions for wider market adoption 2 June 2025
Press Release ARDRI Welcomes Christine Lacy as VP of Wholesale Production—Already Shaping the Future of Non-QM Lending 2 June 2025
Press Release AEye’s Apollo Lidar Sensor Wins Prestigious AIIA Intelligent Perception Industry Leadership Award 2 June 2025
Press Release ENHERTU® Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% Versus THP as First-Line Therapy in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast09 Phase 3 Trial 2 June 2025
Press Release Nebius Group announces private placement of $1 billion in aggregate principal amount of convertible notes 2 June 2025
Press Release How to Maximise the IP in your Business: Building and Managing a Patent Portfolio to Best Support your Business Training Course (ONLINE EVENT: July 3, 2025) – ResearchAndMarkets.com 2 June 2025
Press Release DocGo Announces Upcoming Participation at the Goldman Sachs 46th Annual Global Healthcare Conference 2 June 2025
Press Release Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity 2 June 2025
